158 related articles for article (PubMed ID: 38363461)
1. Assessing Itch Severity: Content Validity and Psychometric Properties of a Patient-Reported Pruritus Numeric Rating Scale in Atopic Dermatitis.
Rams A; Baldasaro J; Bunod L; Delbecque L; Strzok S; Meunier J; ElMaraghy H; Sun L; Pierce E
Adv Ther; 2024 Apr; 41(4):1512-1525. PubMed ID: 38363461
[TBL] [Abstract][Full Text] [Related]
2. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis.
Yosipovitch G; Reaney M; Mastey V; Eckert L; Abbé A; Nelson L; Clark M; Williams N; Chen Z; Ardeleanu M; Akinlade B; Graham NMH; Pirozzi G; Staudinger H; Plaum S; Radin A; Gadkari A
Br J Dermatol; 2019 Oct; 181(4):761-769. PubMed ID: 30729499
[TBL] [Abstract][Full Text] [Related]
3. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis.
Silverberg JI; DeLozier A; Sun L; Thyssen JP; Kim B; Yosipovitch G; Nunes FP; Gugiu PC; Doll HA; Eichenfield LF
Health Qual Life Outcomes; 2021 Oct; 19(1):247. PubMed ID: 34688290
[TBL] [Abstract][Full Text] [Related]
4. Psychometric evaluation of the Worst Pruritus Numerical Rating Scale (NRS), Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS).
Silverberg JI; Leshem YA; Calimlim BM; McDonald J; Litcher-Kelly L
Curr Med Res Opin; 2023 Oct; 39(10):1289-1296. PubMed ID: 37691437
[TBL] [Abstract][Full Text] [Related]
5. Measurement properties of the Patient-Reported Outcomes Information System (PROMIS
Silverberg JI; Lai JS; Patel KR; Singam V; Vakharia PP; Chopra R; Sacotte R; Kantor R; Hsu DY; Cella D
Br J Dermatol; 2020 Nov; 183(5):891-898. PubMed ID: 32107772
[TBL] [Abstract][Full Text] [Related]
6. Psychometric validation and meaningful change thresholds of the Worst Itching Intensity Numerical Rating Scale for assessing itch in patients with chronic kidney disease-associated pruritus.
Vernon MK; Swett LL; Speck RM; Munera C; Spencer RH; Wen W; Menzaghi F
J Patient Rep Outcomes; 2021 Dec; 5(1):134. PubMed ID: 34952964
[TBL] [Abstract][Full Text] [Related]
7. Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial.
Kimel M; Zeidler C; Kwon P; Revicki D; Ständer S
JAMA Dermatol; 2020 Dec; 156(12):1354-1358. PubMed ID: 32936233
[TBL] [Abstract][Full Text] [Related]
8. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).
Silverberg JI; Gooderham MJ; Paller AS; Deleuran M; Bunick CG; Gold LFS; Hijnen D; Calimlim BM; Lee WJ; Teixeira HD; Hu X; Zhang S; Yang Y; Grada A; Platt AM; Thaçi D
Am J Clin Dermatol; 2024 May; 25(3):485-496. PubMed ID: 38528257
[TBL] [Abstract][Full Text] [Related]
9. Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis.
Kimball AB; Naegeli AN; Edson-Heredia E; Lin CY; Gaich C; Nikaï E; Wyrwich K; Yosipovitch G
Br J Dermatol; 2016 Jul; 175(1):157-62. PubMed ID: 26852717
[TBL] [Abstract][Full Text] [Related]
10. Psychometric validation and responder definition of the sleep disturbance numerical rating scale in moderate-to-severe atopic dermatitis.
Puelles J; Fofana F; Rodriguez D; Silverberg JI; Wollenberg A; Dias Barbosa C; Vernon M; Chavda R; Gabriel S; Piketty C
Br J Dermatol; 2022 Feb; 186(2):285-294. PubMed ID: 34608623
[TBL] [Abstract][Full Text] [Related]
11. Validation of the Peak Pruritus Numerical Rating Scale as a Patient-Reported Outcome Measure in Prurigo Nodularis.
Kwatra SG; Rodriguez D; Dias-Barbosa C; Budhiarso I; Fofana F; Vernon M; Gabriel S; Piketty C; Puelles J
Dermatol Ther (Heidelb); 2023 Oct; 13(10):2403-2416. PubMed ID: 37615836
[TBL] [Abstract][Full Text] [Related]
12. Measurement properties of the Patient-Reported Outcomes Information System (PROMIS
Br J Dermatol; 2020 Nov; 183(5):e149-e170. PubMed ID: 33135789
[TBL] [Abstract][Full Text] [Related]
13. Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1.
Simpson EL; Blauvelt A; Silverberg JI; Cork MJ; Katoh N; Mark T; Schneider SKR; Wollenberg A
Am J Clin Dermatol; 2024 Jan; 25(1):139-148. PubMed ID: 37804473
[TBL] [Abstract][Full Text] [Related]
14. The atopic dermatitis itch scale: development of a new measure to assess pruritus in patients with atopic dermatitis.
Martin SA; Brown TM; Fehnel S; Deal LS; Katz EG; Chiou CF
J Dermatolog Treat; 2020 Aug; 31(5):484-490. PubMed ID: 32037925
[No Abstract] [Full Text] [Related]
15. Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2.
Yosipovitch G; Gooderham MJ; Ständer S; Fonacier L; Szepietowski JC; Deleuran M; Girolomoni G; Su JC; Bushmakin AG; Cappelleri JC; Feeney C; Chan G; Thorpe AJ; Valdez H; Biswas P; Rojo R; DiBonaventura M; Myers DE
Am J Clin Dermatol; 2024 Jan; 25(1):127-138. PubMed ID: 37624488
[TBL] [Abstract][Full Text] [Related]
16. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C
Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175
[TBL] [Abstract][Full Text] [Related]
17. Validation of five patient-reported outcomes for atopic dermatitis severity in adults.
Silverberg JI; Margolis DJ; Boguniewicz M; Fonacier L; Grayson MH; Ong PY; Fuxench ZC; Simpson EL
Br J Dermatol; 2020 Jan; 182(1):104-111. PubMed ID: 30972740
[TBL] [Abstract][Full Text] [Related]
18. Onset of Symptom Relief Reported in Daily Diaries of Patients With Atopic Dermatitis Treated With Baricitinib in a United States Clinical Trial (BREEZE-AD5).
Rosmarin D; Casillas M; Chen S; Dawson Z; Pierce E; Zhang H; Bukhalo M; Smith S
J Cutan Med Surg; 2022; 26(3):262-266. PubMed ID: 35086348
[TBL] [Abstract][Full Text] [Related]
19. Validity and reliability of Patient-Reported Outcomes Measurement Information System Global Health scale in adults with atopic dermatitis.
Schwartzman G; Lei D; Yousaf M; Janmohamed SR; Vakharia PP; Chopra R; Chavda R; Gabriel S; Patel KR; Singam V; Kantor R; Hsu DY; Silverberg JI
J Am Acad Dermatol; 2021 Sep; 85(3):636-644. PubMed ID: 33484762
[TBL] [Abstract][Full Text] [Related]
20. Development, Psychometric Validation and Responder Definition of Worst Itch Scale in Children with Severe Atopic Dermatitis.
Paller AS; Yosipovitch G; Weidinger S; DiBenedetti D; Whalley D; Gadkari A; Guillemin I; Zhang H; Eckert L; Chao J; Bansal A; Chuang CC; Delevry D
Dermatol Ther (Heidelb); 2022 Dec; 12(12):2839-2850. PubMed ID: 36269504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
